NeuClone is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of high-quality biosimilar products. The company employs a comprehensive approach to biosimilar development, encapsulated in its "Right from the Start®" strategy, which emphasizes the importance of quality, capacity, and cost. NeuClone's proprietary NeuMAX® platform is a key component of this strategy, utilizing a robust CHO cell-based system designed for the commercial-scale manufacture of complex biologics, including monoclonal antibodies. This platform integrates advanced technologies that enhance the production efficiency and viability of CHO cells, ensuring that the biosimilars developed are clinically identical to their reference products.

NeuClone's pipeline includes over 20 biosimilars targeting various indications, with several candidates already in advanced stages of clinical trials. The company focuses on rigorous analytical and clinical development processes to confirm biosimilarity, which is essential given the inherent variations in biologics. NeuClone's commitment to affordability and patient access is reflected in its diverse portfolio, which includes biosimilars for high-demand therapies such as Stelara® and Herceptin®. By leveraging its expertise in cell biology and analytics, NeuClone aims to meet global healthcare needs while maintaining a strong focus on the quality and integrity of its scientific endeavors.

Australia

NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.


NeuClone

Company Details